VBI Vaccines Inc. (NASDAQ:VBIV) has a beta value of 1.62 and has seen 7,787,450 shares traded in the recent trading session. The company, currently valued at $743.77 Million, closed the recent trade at $3.2258 per share which meant it gained $0.2 on the day or 7.85% during that session. The VBIV stock price is -8.5% off its 52-week high price of $3.5 and 85.57% above the 52-week low of $0.4655. If we look at the company’s 10-day average daily trading volume, we find that it stood at 13.92 Million shares traded. The 3-month trading volume is 11.15 Million shares.

The consensus among analysts is that VBI Vaccines Inc. (VBIV) is a Buy stock at the moment, with a recommendation rating of 1.5. None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. None out of 4 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.22.

VBI Vaccines Inc. (NASDAQ:VBIV) trade information

Sporting 7.53% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Jun 26 when the VBIV stock price touched $3.50-8 or saw a rise of 8.04%. Year-to-date, VBI Vaccines Inc. shares have moved 133.24%, while the 5-day performance has seen it change 22.85%. Over the past 30 days, the shares of VBI Vaccines Inc. (NASDAQ:VBIV) have changed 47.65%. Short interest in the company has seen 14.01 Million shares shorted with days to cover at 1.26.

Wall Street analysts have a consensus price target for the stock at $4.5, which means that the shares’ value could jump 39.5% from current levels. The projected low price target is $3 while the price target rests at a high of $8. In that case, then, we find that the current price level is +148% off the targeted high while a plunge would see the stock lose -7% from current levels.

VBI Vaccines Inc. (VBIV) estimates and forecasts

Figures show that VBI Vaccines Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +119.85% over the past 6 months, with this year growth rate of -58.7%, compared to 9.2% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 8.3% and -5% for the next quarter. Revenue growth from the last financial year stood is estimated to be +4%.

1 analysts offering their estimates for the company have set an average revenue estimate of $200Million for the current quarter. 1 have an estimated revenue figure of $200Million for the next quarter concluding in December 01, 2018. Year-ago sales stood $193Million and $201Million respectively for this quarter and the next, and analysts expect sales will grow by 3.6% for the current quarter and -0.5% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +0% over the past 5 years. Earnings growth for 2020 is a modest +0% while over the next 5 years, the company’s earnings are expected to increase by 0%.